Browsing Tag
radiopharma
2 posts
Is Lantheus (LNTH) the next big radiopharma target after Curium’s takeover move?
Curium’s $7B Lantheus move exposes radiopharma’s scarcity premium. See why oncology imaging assets are becoming M&A targets.
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.